AXIM Biotechnologies, Inc.

$0.01-0.83%($-0.00)
TickerSpark Score
36/100
Weak
30
Valuation
35
Profitability
55
Growth
28
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AXIM research report →

52-Week Range15% of range
Low $0.00
Current $0.01
High $0.03

Companywww.aximbiotech.com

AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation.

CEO
Catalina Valencia
IPO
2014
Employees
6
HQ
San Diego, CA, US

Price Chart

-17.13% · this period
$0.02$0.01$0.00May 20Nov 18May 20

Valuation

Market Cap
$2.04M
P/E
-3.88
P/S
0.00
P/B
-0.19
EV/EBITDA
155.48
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
4.91%
ROIC
32.31%

Growth & Income

Revenue
$0 · -100.00%
Net Income
$-1,043,083 · 70.30%
EPS
$-0.00 · 71.82%
Op Income
$-1,319,652
FCF YoY
20.01%

Performance & Tape

52W High
$0.03
52W Low
$0.00
50D MA
$0.01
200D MA
$0.01
Beta
-0.24
Avg Volume
214.51K

Get TickerSpark's AI analysis on AXIM

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Jan 30, 24Valencia Catalinabuy1,086,216
Mar 15, 24HUEMOELLER JOHN WALTER IIother250,000
Mar 15, 24Valencia Catalinaother7,837,500
Mar 15, 24Schroeder Blakeother35,000
Mar 15, 24Cunningham Robert Lother35,000
Mar 15, 24Scott Timothy Richardother35,000
Mar 15, 24O'Rourke Peterother35,000
Mar 15, 24MALASEK ROBERTother53,500
Mar 15, 24HUEMOELLER JOHN WALTER IIother1
May 23, 23Phinney Kurtother2,000,000

Our AXIM Coverage

We haven't published any research on AXIM yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate AXIM Report →

Similar Companies